Pyramid Studio
A new chapter of therapeutic innovation
Pyramid studio embodies a new way of leading therapeutic innovation. It is a First-of-its-Kind, entrepreneurial-type, venture builder exclusively dedicated to fuel the pipeline of pharmaceutical companies.
Highlyseasoned entrepreneur team with a successfultrackrecord in Pharma & Biotech
Who we are
We are a team of passionate and seasoned healthcare entrepreneurs and industry leaders with longstanding experience across the entire pharmaceutical industry (biotech, pharma, venture capital). We built biotech companies, we worked in Tech Transfer Offices, we performed drug discovery and developed drugs across all stages of development. Our goal is to simplify the innovation value chain to deliver faster therapies to patients.
What we do
We are bridging the gap between science and value. We scout, de-risk and advance breakthrough innovations from Europe’s top academic teams at the door of the clinic for our Pharma partners. We provide them with high-value assets focusing exclusively on Immunology & Inflammation (excluding oncology) covering the fields of rheumatology, internal medicine, neurology, gastro-hepatology and dermatology. Our team brings deep scientific expertise, hands-on experience, and a vast network in this specialized field.
We Scout
…groundbreaking innovations using a unique streamlined process relying on our innovative business model
We build up
…strategic R&D roadmaps to transform groundbreaking discoveries into valuable, patient-centered assets
We collaborate
… with a broad network of KOLs, experts, CROs to challenge our plans and achieve operational excellence
We deliver
… to our partners robust, near-to-the-clinic assets adding value to their drug portfolio
Why
Immuno-Inflammation
Public health burden
Autoimmune and inflammatory diseases (AIDs) are a significant public health burden due to their chronic nature, high prevalence, and impact on quality of life. Patients affected with AIDs are still suffering from high unmet medical need.
Large panel of diseases
Autoimmune diseases are affecting all the components of human body. They occur when the immune system mistakenly attacks the body’s own healthy cells, tissues, or organs. Normally, the immune system defends the body against harmful pathogens, but in autoimmune disorders, this defense system becomes hyperactive and targets self-antigens, leading to chronic inflammation and tissue damage.
Likewise, inflammatory disorders refer to conditions characterized by prolonged inflammation often driven by the immune system’s response to injury, infection, or autoimmunity. This inflammation can lead to tissue damage and dysfunction if not properly controlled.
AIDs include diseases such as rheumatoid arthritis, lupus, and multiple sclerosis, type 1 diabetes which often require long-term treatment.
80
Types of autoimmune
diseases
1
people out of 12 worldwide affected by autoimmune diseases
3nd
cause of morbidity
in the world
$120bn
of annual expenses in the US for autoimmune diseases
What makes us different
We offer a new business model that streamlines the traditional innovation value chain, speeding up the integration of new drugs in our partners portfolio, and the delivery of breakthrough medicines to patients.
Pyramid Studio serves as a one-stop innovation hub embedding the capital and market vision of our partners (Pharma & Biotech companies) with top European academic science. Pyramid provides the other essentials: ability to turn discoveries into useful and valuable drugs, capital efficiency, agility and entrepreneurial mindset.
A purpose-driven model
We act exclusively to fuel the pipeline of Pharmaceutical / large Biotech companies.
A focus on Immuno-inflammation
While our team has accumulated a solid track record in this field, it is marked by persistent high unmet medical needs and unresolved challenges.
A unique business model
We draw interest from pharmaceutical companies by operating as a corporate venture fund.
A fair value distribution
We attract scientists who are looking for a quicker path to reach patients and a more equitable way of sharing value.
Which
benefits to our partners
We offer to our partners an innovative, tailored and effective alternative to traditional external innovation channels e.g. licensing and M&A.
- An access to ground-breaking discoveries stemming out from top-notched science
- An innovation hub structured around industry-driven relationships
- 5 to 10 times cheaper near-to-clinic assets with the potential of breakthrough medicine
- Reduced R&D-related financial burden thanks to a plug-and-play corporate venture firm model
#1
Integrated off-P&L venture builder
#2
Highly skilled & experienced team with proven records
#3
Tailored & Flexible R&D capabilities by-passing competition
#4
Assets acquisition 10-times cheaper than preclinical-stage M&A deals
